Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Results from in-depth KOL and payer interviews and physician surveys provide a current understanding of patient segmentation, influences and preferences, prescribing trends, unmet needs, and more
Discover unmet pharmaceutical needs. Effectively prioritize market opportunities. Deliver optimal returns. Datamonitor Healthcare’s in-depth expert data analysis and robust interactive data tools meet your needs and address your challenges in an ever-changing market.
How it helps
The breadth of coverage ensures you can assess revenue potential and identify competitive threats, market catalysts, and untapped new product development opportunities more holistically than ever before.
How it works
Content created by a global team of award-winning specialist analysts, and an easy-to-use interface that streamlines information gathering make Datamonitor Healthcare the go-to solution for the pharmaceutical and biotechnology industries.
It offers:
Receive accurate replies to your queries in minutes, not hours with 24/7 live customer support. Stay up-to-speed on the latest market developments with customizable email alerts that notify you of updates to the information most important to you.
Datamonitor Healthcare
14 Nov 2022
Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.
Datamonitor Healthcare
By Dominique Fontanilla 14 Nov 2022
There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.
Topic Cancer
Datamonitor Healthcare
14 Nov 2022
This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.
Biomedtracker, Datamonitor Healthcare
22 Sep 2021
Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.
Datamonitor Healthcare, Biomedtracker, Scrip
11 Aug 2021
The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.
Topic Cancer
Datamonitor Healthcare
02 Jul 2021
One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed.
Topic Drug Review Drug Pricing
Biomedtracker, Datamonitor Healthcare
21 May 2021
Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.
Topic Drug Review Coronavirus
Datamonitor Healthcare, Biomedtracker
By Dustin Phan 27 Nov 2020
The effect of COVID-19 on clinical trials, the industry response, and the return to full operations
Topic Coronavirus Clinical Trials
Datamonitor Healthcare
27 Nov 2020
This web event has now ended. You will be able to watch all sessions on demand soon. Register your interest now to receive an update when all sessions are available to view.
Topic Coronavirus
Datamonitor Healthcare
By Niharika Dandamudi 27 Nov 2020
Cardiovascular Diseases (CVDs) are one of the leading causes of disease burden worldwide. This epidemiology overview presents the prevalence of some CVDs and their associated clinical risk factors analyzed by Datamonitor Healthcare.
Topic Cardiovascular
Datamonitor Healthcare
27 Nov 2020
It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.
Topic Biosimilars
Datamonitor Healthcare
17 Nov 2020
As the COVID-19 pandemic continues, governments worldwide have pinned their hopes on returning to normality on the development of a vaccine. With multiple vaccines currently in late-stage trials, there is promise that a successful vaccine will soon be ready.
Topic Coronavirus Vaccines
Scrip, Datamonitor Healthcare
By Stephanie Yip 23 Oct 2020
In 2019, the 10 most lucrative medicines generated combined global sales of $92.5B. Scrip provides insight into these top sellers and the companies behind them, as well US dynamics, global sales forecasts and lifecycle data, with complementary market analysis from Datamonitor Healthcare on diseases targeted, indications, and more.
Topic Drug Review Diseases
Biomedtracker, Datamonitor Healthcare
06 Oct 2020
Valuable insight and expert analyst commentary 2021’s expected drug launches, their indications, commercial potential, regulatory catalysts and more.
Rachel specializes in
27+ years of experience
Connecticut
Amanda specializes in
23+ years of experience
Duncan specializes in
23+ years of experience
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
